Skip to content

DMT: all studies

Page 90 of 160: studies 891 to 900 of 1,593, newest first. Back to the DMT overview

Research

A novel method for quantitative analysis of subjective experience reports: application to psychedelic visual experiences

Frontiers in Psychology December 6, 2024 Sean Noah, Earth Erowid, Fire Erowid et al. 5 citations

Introduction Psychedelic compounds such as LSD, psilocybin, mescaline, and DMT can dramatically alter visual perception. However, the extent to which visual effects of psychedelics consistently vary for different substances is an open question. The visual effects of a given psychedelic compound can range widely both across and within individuals, so datasets with large numbers of participants...

Synergistic, multi-level understanding of psychedelics: three systematic reviews and meta-analyses of their pharmacology, neuroimaging and phenomenology.

Translational Psychiatry December 4, 2024 Kenneth Shinozuka, Katarina Jerotic, Pedro A. M. Mediano et al. 17 citations

Serotonergic psychedelics induce altered states of consciousness and have shown potential for treating a variety of neuropsychiatric disorders, including depression and addiction. Yet their modes of action are not fully understood. Here, we provide a novel, synergistic understanding of psychedelics arising from systematic reviews and meta-analyses of three hierarchical levels of analysis: (1)...

DOI: 10.1038/s41398-024-03187-1 (opens in new tab) Full text (opens in new tab) Consciousness Altered states Psychedelics Brain connectivity

Exploring Therapeutic Potentials and Pathways of Psychedelics in Alzheimer’s Disease‐Related Dementia

Alzheimer s & Dementia December 1, 2024 Jitendra Kumar Sinha, Shampa Ghosh, Krishna Kumar Singh et al. 1 citation

Abstract Background Traditionally associated with recreational and spiritual uses, psychedelics have gained attention in psychotherapy for their therapeutic potential. Functioning as potent 5‐hydroxytryptamine (5HT) agonists, these compounds have demonstrated the ability to enhance neural plasticity by activating serotoninergic and glutamatergic systems. Despite these recognized effects, their...

DOI: 10.1002/alz.084413 (opens in new tab) Dementia Alzheimer's disease Pathology

Relaxed Beliefs After Psychedelics: From Sensory Processing to Mystical States

December 1, 2024 Chloe Lily West Jacobs

This dissertation explores the lasting impact of psychedelic use on brain networks, ranging from basic sensory processing to abstract mystical experiences. Recent research has highlighted the potential of these substances for treating psychiatric disorders, with therapeutic effects persisting weeks after a single dose. We focus on serotonergic psychedelics such as psilocybin and LSD, which are...

DOI: 10.57709/tekc-cw79 (opens in new tab) Full text (opens in new tab) 5-MEO-DMT Psychedelics substances 5-ht2a psychedelics Brain network changes +8

Connected through movement: a feasibility study of online mindfulness-based dance/movement therapy for older adults with age-related cognitive decline during COVID-19.

Aging & Mental Health December 1, 2024 Minjung Shim, Melissa Kavanaugh, Clarissa Lacson et al. 14 citations

Social isolation and loneliness pose significant public health risks, especially among older adults experiencing age-related cognitive decline (ACD). This mixed methods feasibility study explored the potential of an online mindfulness-based dance/movement therapy (M-DMT) program to alleviate loneliness, enhance psychological well-being, and promote physical activity among older adults...

DOI: 10.1080/13607863.2024.2364754 (opens in new tab) Full text (opens in new tab) DMT Mindfulness-based dance/movement therapy Loneliness Mild cognitive impairment +8

Clinical Effects of Psychedelic Substances Reported to United States Poison Centers: 2012 to 2022.

Annals of emergency medicine December 1, 2024 Mark W Simon, Heather A Olsen, Christopher O Hoyte et al. 12 citations

Psychedelic substances use is increasing in the United States (US). The approval of new psychedelic drugs and legalization of natural psychedelic substances will likely further increase exposures and subsequent adverse events. The study objective is to describe the clinical effects, therapies, and medical outcomes of patients with psychedelic exposures reported to US poison centers. We...

DOI: 10.1016/j.annemergmed.2024.06.025 (opens in new tab) Full text (opens in new tab) Psychedelics Substance abuse Drug poisoning Hallucinogens +1

Neuroplasticity and Psychedelics: a comprehensive examination of classic and non-classic compounds in pre and clinical models

arXiv Preprint Archive November 29, 2024 Claudio Agnorelli, Meg J. Spriggs, Kate Godfrey et al. 32 citations preprint

Neuroplasticity, the ability of the nervous system to adapt throughout an organism's lifespan, offers potential as both a biomarker and treatment target for neuropsychiatric conditions. Psychedelics, a burgeoning category of drugs, are increasingly prominent in psychiatric research, prompting inquiries into their mechanisms of action. Distinguishing themselves from traditional medications,...

Full text (opens in new tab) Neuroplasticity Q-bio.nc Q-bio.bm Psychopharmacology +1

Effects of psychoplastogens on blood levels of brain-derived neurotrophic factor (BDNF) in humans: a systematic review and meta-analysis

Molecular Psychiatry November 29, 2024 Adrian Hase, Gregor Hasler, Abigail E. Calder 12 citations

Abstract Background Peripheral levels of brain-derived neurotrophic factor (BDNF) are often used as a biomarker for the rapid plasticity-promoting effects of ketamine, psychedelics, and other psychoplastogens in humans. However, studies analyzing peripheral BDNF after psychoplastogen exposure show mixed results. In this meta-analysis, we aimed to test whether the rapid upregulation of...

DOI: 10.1038/s41380-024-02830-z (opens in new tab) Full text (opens in new tab) Neuroplasticity Brain-derived neurotrophic factor Meta-analysis Neurotrophic factors +4

Pattern of psychedelic substance use: a comparison between populations in Spain and South America using the Psychedelic Use Scale (PUS)

Current Psychology November 21, 2024 Jaime Rojas-Hernández, Lucas F Borkel, Domingo Jesús Quintana Hernández et al. 6 citations

Abstract Psychedelic use has increased in the last decade. However, it is unclear whether the cultural background of the consumers exerts any influence. The aim of the present study was to determine the pattern of psychedelic use in Spain and Spanish-speaking populations in South America and compare these consumption patterns to understand the use of these substances in two culturally distinct...

A Fully Validated LC-MS Quantitation Method for Psychoactive Compounds Found in Native South American Plant Species

Psychoactives November 8, 2024 Jonathan Tran, Aaron Elkins, Simone Vassiliadis et al. 1 citation

Psychoactive drugs are compounds that alter the function of the central nervous system, resulting in changes in perception, mood, cognition, and behavior. A subclass of psychoactive drugs, psychedelics, are hallucinogenic drugs that can trigger psychedelic experiences and possible changes in mental perception. The potential use of psychedelics as a therapeutic has led to an increase in clinical...